Alnylam Pharmaceuticals, Inc.

675 West Kendall St, Cambridge, MA 02142

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company’s pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH.

Click to rate this company
[Total: 0 Average: 0]

3.4

Overall Excellence Rating

Industry

Healthcare

Category

Biotech & Pharmaceuticals

ESG/Ethical Impact

We seek to improve the health and sustainability of our planet. At Alnylam, we understand that our global efforts to advance health equity cannot succeed without considering the planet. The health of the environment affects the lives of every individual around the world, and a changing climate poses new challenges in natural and built environments that directly affect health outcomes. We are addressing the threat of climate change by working to diminish our environmental footprint globally. As we continue to develop RNAi therapeutics, we use cross-functional teams to monitor and improve all aspects of our processes and evaluate for potential environmental and employee safety impacts. Many of these processes are new to the pharmaceutical industry, and we are proud of the path we’ve forged in quality, safety, and environmental best practices. To guide the growth and management of our facilities and systems across Alnylam, we utilize an Environmental Health & Safety Management System framework called EQUINOX. This framework engages our employees as key stakeholders, enables them to build a strong and meaningful EHS culture, and enhances our productivity and EHS performance. EQUINOX acts as a guidepost for every EHS initiative and emphasizes continuous improvement toward best- in-class levels.We actively engage people in tackling the world’s most pressing community and health equity challenges. The core of our vision is to help patients, but we know those patients can only thrive when their communities are also resilient and thriving. Addressing health equity in our communities requires investing in the social determinants of health (SDOH) that affect every individual around the world. Our community strategy is based on collaboration, advocacy, and innovation that will help strengthen communities. Investment in our communities is core to our corporate responsibility theme, “accepting challenges to improve the health of humanity.” We know we can, as a company with more than 2,000 employees, have a positive impact on the health and well-being of the world. We maintain a strategic portfolio of grantmaking and partnerships, volunteerism and matched giving that brings us together with leaders in the field to enable community development and resilience.Alnylam’s strategy, P5x25, outlines our vision of becoming a top- tier biotech company by 2025. This goal requires Alnylam’s growth and expansion but we cannot succeed without a deep underlying commitment to good governance and operating with integrity in all we do. As we scale, we will continuously advance the strongest ethics, compliance, and legal standards, ensuring corporate responsibility endures as we evolve. Alnylam’s Board of Directors (Board) is focused on leading with strong governance and integrity. Led by Board Chair Amy W. Schulman, our Board includes representatives from diverse populations, with six women and two people of color as members. Alnylam’s CEO Yvonne Greenstreet, MBChB, serves on the Board and manages our Executive Leadership Team (ELT), comprised of Alnylam’s most senior executives.Alnylam specializes in RNA interference (RNAi) therapies. Its focus on innovative genetic treatments contributes to its financial stability. Alnylam generates revenue from the development and commercialization of RNAi therapies. The company’s RNAi therapies offer promising treatments for genetic disorders, contributing to its financial performance and impact on patients with rare diseases. Veeva provides cloud-based software solutions for life sciences companies. Its technology offerings contribute to its financial stability. Veeva generates revenue from subscription services for its cloud-based software solutions. The company’s software solutions enhance operational efficiency and compliance for life sciences companies, impacting both its revenue and the industry.We are proud of our commitment to publishing truthful, ethical, and transparent information about the findings of our clinical trials. Disclosure of clinical study information is not only important for advancing patient care, but also for medical research and to engender public confidence in the safety of investigational and newly approved therapies. We register clinical trial information for Alnylam- sponsored Phase I-IV clinical studies on Clinicaltrials.gov, EudraCT, and other registry websites. We also voluntarily register and provide study information on healthy volunteer studies, observational trials, and expanded access programs on Clinicaltrials.gov. We work to share the results of clinical trials with the scientific community openly, regardless of whether the results of the study are positive or negative. We submit manuscripts for publication in peer-reviewed scientific and medical journals and congresses in our industry. In addition, we share de-identified patient-level datasets with qualified scientific and medical researchers.

Eligible Awards

Coming Soon

Claim Your Award Badges

Do you work with Us

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer.

Awards Received

2023

Revenues

$1,000,000,000.00

Website Traffic

Employee Rating

3.8

Customer Rating

4.4

Company Size

5000-10000

ESG Risk Rating

4

We’re Happy to Help.

Do you have questions about your ranking, our projects, or why you’re not on the list?
Scroll to Top

Excellence In My Industry

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business in your specific industry – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best Practice Certified

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best of Best Practices

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the top 20 companies in your industry that has met the criteria for our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Newsweek Excellence 1000

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the Top 1000 companies that demonstrate excellence across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.